Structure Therapeutics Inc. Sponsored ADR (GPCR)
(Delayed Data from NSDQ)
$16.78 USD
-0.81 (-4.60%)
Updated Aug 4, 2025 04:00 PM ET
After-Market: $16.76 -0.02 (-0.12%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth F Momentum F VGM
Fundamental Charts
About Earnings Yield (TTM)
The company's trailing twelve month (TTM) Earning Yield is used to determine whether the company is undervalued or overvalued. The Earning yield an indicator of the company's earnings and the price paid for the stock. The calculation is the inverse of the P/E ratio. The most common use of the Earnings ratio is to compare it to other stocks and to compare the yields to the 10 Year T-Bill. If earnings go up, the yield goes up. If earnings go down, so does the yield. For example: If the yield on the S&P 500 is greater than the 10 Year T-Bill, stocks would be considered undervalued.
GPCR 16.78 -0.81(-4.60%)
Will GPCR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GPCR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GPCR
LLY Stock Up as Oral GLP-1 Pill Meets Goals in First Phase III Study
NVO, LLY, GPCR & VKTX Stocks Gain Following PFE's Obesity Study Setback
GPCR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for October 23rd
Does Structure Therapeutics Inc. Sponsored ADR (GPCR) Have the Potential to Rally 115.8% as Wall Street Analysts Expect?
NVO Oral Obesity Pill Tops Wegovy; LLY, VKTX, GPCR Stocks Rise
Other News for GPCR
Structure Therapeutics (GPCR) Gains Analyst Support with Buy Rating
Structure Therapeutics initiated with bullish view at Clear Street, here's why
Goldman Sachs Initiates Coverage on Structure Therapeutics (GPCR) | GPCR Stock News
Structure Therapeutics initiated with Early-Stage Biotech at Goldman Sachs
Structure Therapeutics, Inc. Sponsored ADR (GPCR) Gets a Buy from Guggenheim